Home About Science Development Publications NIA24 Contact

Niadyne Pharma is developing pharmaceutical indications for two dermatology conditions with high market potential, a first in class indication for prevention of pre-cancerous actinic keratosis skin lesions and treatment of mild to moderate plaque psoriasis for patients where the risk and costs of treatment with biologics is not warranted. NPI believes Nia-114's efficacy profile represents a new paradigm in dermatology such that it has the potential to be "a pipeline within a drug" due to its ability to improve the skin barrier and normalize immune function in a wide range of dermatology diseases and conditions. Additional potential of the technology for other conditions with impaired skin barrier integrity is also described.

Actinic Keratoses Prevention

Psoriasis Treatment

Additional Clinical Potential of the Technology

Home